Apparent cure of Graves‐Basedow disease after sibling allogeneic bone marrow transplantation

Díez, Santiago Gómez; Banias, Helena; Díez-Martín, José L.; Briz, Montserrat; Estrado, Janvier; Barceló, B

doi:10.1046/j.1365-2265.1999.00568.x

Cited by 11 publications

(5 citation statements)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12][13][14][15][16][17][18][19][20][21][22] The AID preceded the onset of aplastic anemia by 0.2-25 (median 3) years. Prior treatment for AID included gold salts, antirheumatic or thyroistatic drugs in at least 10 patients.…”

Section: Allogeneic Sctx For Aplastic Anemia and A Concomitant Autoimmentioning

confidence: 99%

Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases

Hinterberger

Hinterberger-Fischer

Marmont

2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:To determine the role of allogeneic, autologous and syngeneic hemopoietic stem cell transplantation (SCTx) as a treatment for severe autoimmune disease (AID) we performed a literature search employing Medline, Cancer Lit and abstract books for reports on transplants for blood disorders and a concomitant AID. All reviews, case reports and abstracts available between June 1977 and September 2001 were used and attempts made to update them by e-mail by the corresponding authors. Disease-free survival (DFS) after allogeneic SCTx for 23 patients with severe aplastic anemia was 78% at 16 years and survival in unmaintained remission of concomitant AID was 64% at 13 years. DFS after allogeneic SCTx for 24 patients with hematologic malignancies was 87% at 15 years and survival in unmaintained remission for concomitant AID was 70% at 11 years. DFS after autologous SCTx for 24 patients with hematologic malignancies was 48% at 6 years and survival in unmaintained remission for concomitant AID was 29% at 3 years. Among 30 patients given allogeneic SCTx 19 developed graft-versus-host disease (GVHD) and 11 did not. Upon clinically justified discontinuation of all immunosuppressive therapy, 3/11 patients without GVHD relapsed with their concomitant AID (freedom of AID-relapse 69% at 9 years), whereas none of 19 patients with GVHD did so (log rank: P ‫؍‬ 0.0135). Freedom of AID-relapse was superior after allo SCTx compared to autologous SCTx (89% at 18 years vs 38% at 5 years; log rank: P ‫؍‬ 0.0002). Our data suggest that a graft-versus-autoimmunity effect after allogeneic hemopoietic SCTx mediates elimination of autoimmunity.

show abstract

Section: Allogeneic Sctx For Aplastic Anemia and A Concomitant Autoimmentioning

confidence: 99%

Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases

Hinterberger

Hinterberger-Fischer

Marmont

2002

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…A different and probably unrelated association between SAA and Graves disease is the development of Graves disease following allogeneic hematopoietic stem cell transplantation for SAA, which suggests transfer of auto/allo‐reactive T‐cells 9,10. Graves Disease was cured in a 29‐year‐old patient, who underwent allogeneic hematopoietic stem cell transplantation for SAA 11.…”

Section: Discussionmentioning

confidence: 99%

Remission of aplastic anemia induced by treatment for Graves disease in a pediatric patient

Das¹,

Wherrett²,

Dror³

2007

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Aplastic anemia (AA) is mediated by T-cell autoimmunity in the majority of cases; it is rare and mostly idiopathic in children. We describe a child, who developed AA following Graves' disease which could not be attributed to antithyroid drugs. We hypothesized that both diseases were caused by similar autoimmune process. We monitored the blood counts and did not administer any conventional treatment for AA assuming that the existing anti- hematopoietic stem cell humoral and cellular immunity might subside with induction of remission of Grave's disease. The child went into complete remission with the treatment of the Graves' disease.

show abstract

“…Two previous reports have each described a patient with SAA, when Grave's disease developed months to years after a matched sibling BMT, in both the donor and the recipient, suggesting that immunopoietic reconstitution from the donor, along with a genetic predisposition, led to Grave's disease in these patients with SAA (Holland et al , 1991; Ichihashi et al , 1992). Another report of a 30‐year‐old patient with concomitant Grave's and SAA who was cured of both diseases by a BMT implies that immune alteration of the patient's marrow by BMT led to a cure of both autoimmune disorders (Diez et al , 1999). There are two additional reports of immune hyperthyroidism and SAA in two patients aged 30 and 35 years (Hinterberger‐Fischer et al , 1994), and in a 25‐year‐old (Todd & Todd, 1999).…”

Section: Discussionmentioning

confidence: 99%

Severe aplastic anaemia and Grave's disease in a paediatric patient

Kumar

Goldman

2002

Br J Haematol

View full text Add to dashboard Cite

Summary. Severe aplastic anaemia (SAA) is considered to be an autoimmune disorder affecting the haematopoietic cells and most often is idiopathic. An association between SAA and other autoimmune diseases is rare and has been described in adults for eosinophilic fasciitis, thymomas, systemic lupus erythematosus and thyroid disorders. We describe the first paediatric patient with chronic relapsing SAA and Grave's disease. We discuss the difficulty in diagnosis of Grave's disease, the possibility of its manifestation due to withdrawal of immunosuppressants, and issues to consider in the treatment of this disease in the setting of bone marrow failure.

show abstract

Apparent cure of Graves‐Basedow disease after sibling allogeneic bone marrow transplantation

Cited by 11 publications

References 10 publications

Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases

Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases

Remission of aplastic anemia induced by treatment for Graves disease in a pediatric patient

Severe aplastic anaemia and Grave's disease in a paediatric patient

Contact Info

Product

Resources

About